Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer (PROPOSE)
Effect of Intravaginal Prasterone on Genitourinary Syndrome in Women in Menopause With Previous Breast Cancer or Currently Under Treatment With Endocrine Therapy for Breast Cancer With Aromatase Inhibitor +/- LHRHa
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: SILVIA MARTELLA
- Phone Number: 0039 02 943742104
- Email: silvia.martella@ieo.it
Study Locations
-
-
-
Milan, Italy, 20141
- European Institute of Oncology
-
Contact:
- SILVIA MARTELLA
- Phone Number: 0039 02 943742104
- Email: silvia.martella@ieo.it
-
Principal Investigator:
- SILVIA MARTELLA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed breast cancer, completely excised
- Natural or iatrogenic menopausal status
- No evidence of distant metastasis
- Self-identified moderate to severe symptoms of genitourinary syndrome
- Normal kidney and liver function
- Written Informed Consent signed and dated by patient
- Negative Papanicolau (Pap) Smear Cytology Test within 1 year prior to enrollment
Exclusion Criteria:
- Vaginal or uterine bleeding of unknown origin
- Current diagnosis of any non-breast malignancy
- Metastatic disease
- Currently on chemiotherapy
- Currently on treatment with tamoxifen
- Mentally incompetent or evidence of active substance or alcohol abuse
- Endometrial hyperplasia
- Pregnancy or lactation
- Currently use of other vaginal therapy for the same purpose (if present, they have to be stopped 15 days before baseline visit)
- Clinically significant metabolic or endocrine disease not controlled by medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: intravaginal Prasterone
|
Prasterone 6.5 mg vaginal tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Establish subjective improvement in genitourinary symptomatology at intervals marked by the study
Time Frame: From enrollment to after 3 months after the end of treatment
|
To establish the improvement in vulvovaginal and urinary symptoms, by subjective evaluation at baseline, at 12 weeks and after 1 and 3 months after the end of the treatment.
Establish tissue trophism improvement through gynecological evaluation, the use of validated scales (Vaginal Health Index), and determination of the maturation index on vaginal spatula, measure serum estradiol during and after treatment
|
From enrollment to after 3 months after the end of treatment
|
|
evaluation of vulvovaginal and urinary symptoms
Time Frame: 6 months
|
evaluation of vaginal dryness, dyspareunia, pruritis, burning and dysuria with a 0 to 4 score (0: absence, 1: mild, 2: moderate, 3: severe, 4: very severe)
|
6 months
|
|
improvement in vaginal signs
Time Frame: 6 months
|
To establish the improvement in vaginal signs using the Vaginal Health Index Scale (VHI)
|
6 months
|
|
evaluation fo maturation index
Time Frame: 6 months
|
To assess the maturation index (as percentage of superficial, intermediate and parabasal cells) in the vaginal mucosa
|
6 months
|
|
grade of satisfaction
Time Frame: 6 months
|
To report the grade of satisfaction as measured by the Global Response Assessment at the end of the study
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: SILVIA MARTELLA, European Institue of Oncology
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UID 2966
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.